^
Association details:
| Biomarker: | BCL2 overexpression + CCND1 overexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Venetoclax monotherapy is feasible and efficient in patients with bcl-2 overexpressing relapsed/refractory multiple myeloma at high- risk sites: a case series
Published date:
08/28/2021
Excerpt:
...three cases of bcl-2 IHC positive RRMM patients...two of three patients showed a strong cyclin D1 expression....Regarding the first case, two months after venetoclax beginning, IgG levels dropped to normal range reaching a VGPR (Duration of response (DOR) is 7 months). In the second case a CR was achieved in PET-CT and MRI scans 5 months after beginning of venetoclax treatment (DOR 15 months). A follow-up PET-CT staging of the third case showed a CR of the previously described extramedullary manifestations three months after venetoclax dosing.
